FDA Approves CARVYKTI® and ABECMA for Early Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma
On April 5, 2024, the FDA revised the indications of both approved CAR T cell therapies for relapsed multiple myeloma to allow the use of these...